SB4464, the FAIR Labels Act of 2026, would require new labeling and regulatory rules for cell-cultivated protein products and plant-based alternative protein products. The bill directs the Secretary of Agriculture and the Secretary of Health and Human Services to revise their existing memorandum of understanding on oversight of cell-cultivated protein so that USDA and FDA responsibilities are more clearly divided, with HHS handling premarket consultation, cell-line oversight, and related manufacturing controls, and USDA implementing the bill’s amendments and conducting inspections and enforcement as needed.
The bill amends the Federal Meat Inspection Act and the Poultry Products Inspection Act to define “cell-cultivated protein product” and require prominent labels stating “cell-cultivated,” along with disclosures that the product is derived from sources other than meat or poultry and a disclaimer that it is not naturally produced meat from a live animal or bird. It also requires that these products be regulated in the same manner as meat and poultry products under the applicable inspection laws. For plant-based alternative protein products, the bill adds a federal definition and requires labels to identify them as “plant-based alternative protein product” and to state that they are not derived from naturally produced meat or poultry. Finally, USDA, in consultation with HHS, must develop common standards of identity for both categories within 180 days of enactment.
In practical terms, the bill would expand federal labeling and inspection requirements for alternative proteins and would likely affect manufacturers, processors, and retailers of cultivated meat, cultivated poultry, and plant-based meat analogs. It would also create new statutory definitions and misbranding standards under the meat, poultry, and food labeling laws, while giving USDA and HHS additional implementation and enforcement responsibilities. The measure is framed as a consumer-information bill, but it also functions as a regulatory clarification bill for emerging protein technologies.
The available context shows no committee debate or recorded votes, so there is no documented legislative sentiment beyond the bill’s bipartisan introduction by Senators Ricketts and Fetterman. The title and text suggest a consumer transparency rationale, and the bipartisan sponsorship indicates at least some cross-party support for clearer labeling rules. Because there are no transcripts or votes, broader support or opposition cannot be measured from the provided record.
The main points of contention likely concern whether the bill’s labeling requirements are neutral consumer disclosures or whether they single out cultivated and plant-based products in a way that could disadvantage them in the marketplace. Potential disputes may also involve the scope of USDA versus FDA authority, the feasibility of the required disclaimers, and whether the bill’s definitions and standards of identity are sufficiently precise for products that are still developing technologically.
The bill would amend the Federal Meat Inspection Act, the Poultry Products Inspection Act, and the Federal Food, Drug, and Cosmetic Act to create new federal definitions, labeling rules, and standards of identity for cell-cultivated protein products and plant-based alternative protein products. It would also require USDA and HHS to revise their oversight agreement and assign additional inspection, consultation, and enforcement responsibilities related to cultivated protein production and labeling.
There is no recorded committee transcript or vote history in the provided material, so sentiment cannot be measured from debate or roll call. The bill’s bipartisan introduction by Senators Ricketts and Fetterman suggests some cross-party interest in consumer labeling transparency, and the text is presented as a consumer-information measure rather than a restriction on product sales.
The likely areas of contention are the bill’s mandatory label language, especially the required “cell-cultivated” and “plant-based alternative protein product” descriptors and the accompanying disclaimers that the products are not derived from naturally produced meat or poultry. Stakeholders in the cultivated meat and plant-based food industries may view these requirements as burdensome or stigmatizing, while supporters are likely to argue they prevent consumer confusion. Another possible dispute is the allocation of regulatory authority between USDA and FDA and whether the bill’s standards of identity should be set now for evolving technologies.